Metabolic profile of patients with coronary artery disease and comorbid obesity.
Cardiovascular diseases (CVD) are the leading cause of death worldwide. Most CVD can be prevented by modification of such risk factors as tobacco use, obesity and unhealthy diet, physical inactivity and harmful use of alcohol. Patients with CVD or who are at high cardiovascular risk due to the pres...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dnipro State Medical University
2018-05-01
|
| Series: | Medičnì Perspektivi |
| Subjects: | |
| Online Access: | http://journals.uran.ua/index.php/2307-0404/article/view/126943 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846098212737253376 |
|---|---|
| author | T. Maksymets A. Faynyk E. Sklyarov |
| author_facet | T. Maksymets A. Faynyk E. Sklyarov |
| author_sort | T. Maksymets |
| collection | DOAJ |
| description | Cardiovascular diseases (CVD) are the leading cause of death worldwide. Most CVD can be prevented by modification of such risk factors as tobacco use, obesity and unhealthy diet, physical inactivity and harmful use of alcohol. Patients with CVD or who are at high cardiovascular risk due to the presence of risk factors such as dyslipidemia, hypertension, diabetes mellitus type 2, need early detection and management of these states. The article describes differences between metabolic profile of patients with obesity and coronary artery disease. The study included 58 patients. They were divided into 3 groups: 1st - patients with BMI <30 and CAD, 2nd - patients with BMI>30 and CAD, and 3rd - patients with BMI>30. 1st and 2nd group of patients were treated with atorvastatin in the dose of 40 mg for 2 years, 3rd - untreated. The results indicate that significant difference was faund in the lipid profile between groups of patients treated with atorvastatin in the dose of 40 mg . Transaminases and uric acid levels were different but within the reference range. The difference was found in serum glucose, insulin and HOMA-IR between participants of the 2-nd and other groups. We observed significant insulin resistance in the group of patients with coronary heart disease, obesity, treated with atorvastatin. So, administration of atorvastatin to the patients with IHD and obesity may negatively impact carbohydrate exchange and serve as a possible cause of diabetes melitus type 2 development. |
| format | Article |
| id | doaj-art-aa36e1dd2d9b4bfd92583ed1e3c7e079 |
| institution | Kabale University |
| issn | 2307-0404 |
| language | English |
| publishDate | 2018-05-01 |
| publisher | Dnipro State Medical University |
| record_format | Article |
| series | Medičnì Perspektivi |
| spelling | doaj-art-aa36e1dd2d9b4bfd92583ed1e3c7e0792025-01-02T01:49:24ZengDnipro State Medical UniversityMedičnì Perspektivi2307-04042018-05-01231(part2)515610.26641/2307-0404.2018.1(part2).126943126943Metabolic profile of patients with coronary artery disease and comorbid obesity.T. MaksymetsA. FaynykE. SklyarovCardiovascular diseases (CVD) are the leading cause of death worldwide. Most CVD can be prevented by modification of such risk factors as tobacco use, obesity and unhealthy diet, physical inactivity and harmful use of alcohol. Patients with CVD or who are at high cardiovascular risk due to the presence of risk factors such as dyslipidemia, hypertension, diabetes mellitus type 2, need early detection and management of these states. The article describes differences between metabolic profile of patients with obesity and coronary artery disease. The study included 58 patients. They were divided into 3 groups: 1st - patients with BMI <30 and CAD, 2nd - patients with BMI>30 and CAD, and 3rd - patients with BMI>30. 1st and 2nd group of patients were treated with atorvastatin in the dose of 40 mg for 2 years, 3rd - untreated. The results indicate that significant difference was faund in the lipid profile between groups of patients treated with atorvastatin in the dose of 40 mg . Transaminases and uric acid levels were different but within the reference range. The difference was found in serum glucose, insulin and HOMA-IR between participants of the 2-nd and other groups. We observed significant insulin resistance in the group of patients with coronary heart disease, obesity, treated with atorvastatin. So, administration of atorvastatin to the patients with IHD and obesity may negatively impact carbohydrate exchange and serve as a possible cause of diabetes melitus type 2 development.http://journals.uran.ua/index.php/2307-0404/article/view/126943insulin resistancestatins, obesitycoronary artery disease |
| spellingShingle | T. Maksymets A. Faynyk E. Sklyarov Metabolic profile of patients with coronary artery disease and comorbid obesity. Medičnì Perspektivi insulin resistance statins, obesity coronary artery disease |
| title | Metabolic profile of patients with coronary artery disease and comorbid obesity. |
| title_full | Metabolic profile of patients with coronary artery disease and comorbid obesity. |
| title_fullStr | Metabolic profile of patients with coronary artery disease and comorbid obesity. |
| title_full_unstemmed | Metabolic profile of patients with coronary artery disease and comorbid obesity. |
| title_short | Metabolic profile of patients with coronary artery disease and comorbid obesity. |
| title_sort | metabolic profile of patients with coronary artery disease and comorbid obesity |
| topic | insulin resistance statins, obesity coronary artery disease |
| url | http://journals.uran.ua/index.php/2307-0404/article/view/126943 |
| work_keys_str_mv | AT tmaksymets metabolicprofileofpatientswithcoronaryarterydiseaseandcomorbidobesity AT afaynyk metabolicprofileofpatientswithcoronaryarterydiseaseandcomorbidobesity AT esklyarov metabolicprofileofpatientswithcoronaryarterydiseaseandcomorbidobesity |